Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression

Table 3 Correlation between expression of ASH1L and clinicopathological characteristics

Variable	High expression (n = 44)	Low expression (n = 67)	P value
Gender (M/F)	37/7	56/11	0.944
Age (year)	54.73 ± 8.56	54.63 ± 9.67	0.814
Hepatitis (HBV/HCV/none)	36/4/4	52/9/5	0.487
Cirrhosis (Y/N)	32/12	64/2	0.25
MELD score	7.67 (5.57-9.65)	6.62 (5.43-8.09)	0.071
Number of tumors (multiple/single)	30/14	33/34	0.05
Maximum diameter of tumor (cm)	3.50 (2.00-6.00)	3.00 (2.00-6.00)	0.954
Satellite cooker (Y/N)	12/32	11/56	0.169
MVI (Y/N)	16/28	12/55	0.029
Tumor differentiation (well/moderate/poor/undifferentiation)	0/28/15/1	1/40/19/7	0.649
Clinicopathological stage (I/II/III/IV)	7/12/25/0	20/22/25/0	0.032
Relapse states (N/Y)	22/22	47/22	0.002
Vital states (alive/dead)	25/19	56/11	0.033

Y: Yes; N: No; M: Male; F: Female; MELD: Model for end-stage liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus.